Aptevo Therapeutics (APVO) Expected to Announce Quarterly Earnings on Tuesday

Aptevo Therapeutics (NASDAQ:APVO) is expected to be posting its results after the market closes on Tuesday, May 12th. Analysts expect Aptevo Therapeutics to post earnings of ($5.60) per share for the quarter.

Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings results on Thursday, March 26th. The biotechnology company reported $118.23 EPS for the quarter, topping the consensus estimate of ($8.10) by $126.33. On average, analysts expect Aptevo Therapeutics to post $-21 EPS for the current fiscal year and $-19 EPS for the next fiscal year.

Aptevo Therapeutics Price Performance

APVO stock opened at $4.97 on Friday. Aptevo Therapeutics has a 12 month low of $3.80 and a 12 month high of $258.01. The firm has a market cap of $5.86 million, a PE ratio of 0.00 and a beta of 1.64. The firm has a 50 day simple moving average of $5.07 and a 200 day simple moving average of $12.38.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Wall Street Zen raised Aptevo Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 29th. Weiss Ratings lowered shares of Aptevo Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a report on Friday, April 24th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold”.

Institutional Investors Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned about 1.16% of Aptevo Therapeutics at the end of the most recent reporting period. 8.06% of the stock is currently owned by institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.